Stock Market Wire News Logo
Stock Market Wire News Logo
    • Login
    • Sign Up

Ad

Trending Stock Alerts

GLYC Stock - GlycoMimetics Stock Trading


home / stock / glyc

GLYC GLYC Quote GLYC Short GLYC News GLYC Articles GLYC Message Board

MWN AI Summary *

GlycoMimetics Inc. (NASDAQ: GLYC) is a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for the treatment of cancer and other serious diseases. Founded in 2003 and headquartered in Rockville, Maryland, GlycoMimetics leverages its proprietary glycomimetic technology platform to create drug candidates that mimic the structure and function of carbohydrates involved in cell-cell interactions, an area critical to various pathological processes, including tumor growth and metastasis.

The company’s lead candidate, uproleselan (GMI-1271), has been designed to target and block specific interactions between leukemic cells and their bone marrow microenvironment, with an aim to enhance the efficacy of existing therapies for acute myeloid leukemia (AML). Uproleselan has been evaluated in several clinical trials, demonstrating promise in improving treatment outcomes for patients, especially in combination with standard chemotherapy.

In addition to uproleselan, GlycoMimetics is exploring other compounds in its pipeline, targeting various hematologic malignancies and solid tumors. The company collaborates with leading academic institutions and pharmaceutical companies to expedite the development of its drug candidates.

GlycoMimetics has garnered attention in the biotechnology sector not only for its innovative approach but also for its strategic partnerships and collaborations. The company’s research has significant implications in expanding treatment options for cancer patients, an area with a substantial unmet medical need.

As of October 2023, while the market has seen fluctuations, GlycoMimetics continues to be viewed as a potential player in the oncology space. Investors keep a close eye on its clinical trial results and the trajectory of uproleselan, as success in these areas could bolster the company’s position within the competitive biotechnology landscape.

MWN AI Analysis *

GlycoMimetics Inc. (NASDAQ: GLYC) is a biotechnology company focused on developing and commercializing novel therapies for underserved patient populations with serious diseases, such as cancer and sickle cell disease. As of October 2023, investors looking to evaluate GLYC must consider both the company's scientific prospects and the broader market dynamics impacting biotechnology stocks.

The company’s lead asset, uproleselan, has shown promise in clinical trials for acute myeloid leukemia (AML). The recent FDA acceptance of their New Drug Application (NDA) marks a pivotal point for GlycoMimetics, as it potentially positions the company for significant revenue generation if the drug is approved. Investors should watch for upcoming clinical data releases and the outcomes of any ongoing trials, as these could significantly influence market sentiments and stock performance.

From a financial perspective, GlycoMimetics' balance sheet should also be a consideration. As a developmental-stage biotech, it is crucial to analyze its cash runway and how effectively it can fund ongoing trials. Recent financing efforts, partnerships, or collaborations may provide insights into its funding strategy and potential avenues for revenue generation.

Additionally, the broader biotechnology market is subject to regulatory scrutiny and volatility, which can affect stock prices significantly. Factors such as changes in healthcare policies, capital market conditions, or market sentiment towards biotech can create fluctuations that investors must navigate.

Lastly, keeping an eye on competitor developments in the space is essential. Innovations or setbacks from industry peers can impact market perceptions of GlycoMimetics’ potential success.

In summary, GlycoMimetics presents an intriguing opportunity given its pipeline and market position. However, potential investors should conduct thorough due diligence, considering both the clinical and financial landscapes, as well as the overall environment in the biotechnology sector, before making investment decisions.

* MWN AI Summary and Analysis is based on asking OpenAI to summarize and analyze the company and stock symbol.


About | GlycoMimetics Inc. (NASDAQ:GLYC)

GlycoMimetics Inc is a clinical stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it plays in inflammation, cancer, and infection.

Quote | GlycoMimetics Inc. (NASDAQ:GLYC)

Last:$0.157
Change Percent: -6.5%
Open:$0.1672
Close:$0.157
High:$0.17
Low:$0.153
Volume:1,069,391
Last Trade Date Time:06/13/2025 03:40:37 pm

News | GlycoMimetics Inc. (NASDAQ:GLYC)

  • GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals

    — GlycoMimetics Board of Directors approves 1-for-100 reverse stock split — GlycoMimetics, Inc. (Nasdaq: GLYC) (“GlycoMimetics”) today announced that its stockholders have approved the proposed merger (the “Merger”) with Crescent Bioph...

    • June 05, 2025 04:01:00 pm

    • |
    • Business Wire
    • |
      • GLYC Stock
      • GLYC Quote
      • GLYC Short
      • GLYC News
      • GLYC Articles
      • GLYC Message Board
  • Expected US Company Earnings on Thursday, May 15th, 2025

    Replimune Group Inc. (REPL) is expected to report $-0.75 for Q4 2025 Adcore (ADCOF) is expected to report for Q1 2025 Equillium Inc. (EQ) is expected to report $-0.22 for Q1 2025 Credicorp Ltd. (BAP) is expected to report $5.31 for Q1 2025 Pelangio Exploration Inc (PGXPF) is expec...

    • May 15, 2025 07:00:39 am

    • |
    • US Earnings Reports
    • |
      • GLYC Stock
      • GLYC Quote
      • GLYC Short
      • GLYC News
      • GLYC Articles
      • GLYC Message Board

Message Board Posts | GlycoMimetics Inc. (NASDAQ:GLYC)

Subject By Source When
whytestocks: $GLYC News Article - GlycoMimetics to Report Fourth Quarter and 2022 Full Year Financia whytestocks investorshangout 03/16/2023 12:50:50 PM
Dilution. willlbone investorshub 02/15/2023 8:28:30 PM
Reversal INFINITI investorshub 02/15/2023 4:04:52 PM
Picked up a few heavy racks of shares TechandBio investorshub 01/04/2023 12:37:49 AM
whytestocks: $GLYC News Article - Best Penny Stocks To Buy Now? 4 Stocks Under $4 To Watch whytestocks investorshangout 12/28/2022 6:25:45 PM

MWN AI FAQ **

What are the latest developments in GlycoMimetics Inc. GLYC's clinical trials, and how might they impact the company’s future market position?

As of October 2023, GlycoMimetics Inc. has advanced its clinical trials for GMI-1359 and hopes positive results will bolster its market position by attracting partnerships and enhancing its portfolio in hematological malignancies and rare diseases.

How has GlycoMimetics Inc. GLYC responded to recent regulatory changes, and what implications could this have for its product pipeline?

GlycoMimetics Inc. has strategically adjusted its clinical development plans in response to recent regulatory changes, potentially accelerating its product pipeline by prioritizing therapies that align with the updated approval criteria and market needs.

What are the financial forecasts for GlycoMimetics Inc. GLYC in the next fiscal year, especially in relation to revenue growth and R&D investments?

GlycoMimetics Inc. (GLYC) is expected to experience modest revenue growth in the next fiscal year, driven by potential drug approvals, while continuing to prioritize substantial investments in R&D to advance their pipeline of treatments.

How does GlycoMimetics Inc. GLYC plan to navigate competitive pressures within the biotech sector, particularly concerning its unique therapies?

GlycoMimetics Inc. plans to navigate competitive pressures in the biotech sector by leveraging its unique therapies focused on innovative glycomimetic technology, enhancing strategic partnerships, and emphasizing robust clinical trials to demonstrate efficacy and safety.

** MWN AI Questions are based on asking OpenAI to ask and answer four questions about the company and stock symbol.

Stock Information

Get GLYC Alerts

News, Short Squeeze, Breakout and More Instantly...

GlycoMimetics Inc. Company Name:

GLYC Stock Symbol:

NASDAQ Market:

-6.5% G/L:

$0.157 Last:

1,069,391 Volume:

$0.1672 Open:

$0.157 Close:

GlycoMimetics Inc. Website:

GlycoMimetics Inc. Logo

Ad

Trending Stock Alerts
RECENT GLYC NEWS
  • GLYC - GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals

    — GlycoMimetics Board of Directors approves 1-for-100 reverse stock split — GlycoMimetics, Inc. (Nasdaq: GLYC) (“GlycoMimetics”) today announced that its stockholders have approved the proposed merger (the “Merger”) with Crescent Bioph...

  • GLYC - Expected US Company Earnings on Thursday, May 15th, 2025

    Replimune Group Inc. (REPL) is expected to report $-0.75 for Q4 2025 Adcore (ADCOF) is expected to report for Q1 2025 Equillium Inc. (EQ) is expected to report $-0.22 for Q1 2025 Credicorp Ltd. (BAP) is expected to report $5.31 for Q1 2025 Pelangio Exploration Inc (PGXPF) is expec...

  • GLYC - GLYC - Historical Price Movements Surrounding Earnings

    2025-05-14 18:48:08 ET GlycoMimetics, Inc. (GLYC) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 6.19%. The average open to low on the day of earnings was -4.18%. The average open to cl...

  • Research
  • Stock Search
  • News Releases
  • Articles
  • Topics
  • Message Boards
  • Trending Stocks
  • Trending Feed
  • Trending Alerts
  • Watchlist
  • Short Information
  • Stock Wall
  • Link Twitter
  • Sign Up
  • Login
  • Contact

Link your X Account

Link your X Account to Market Wire News

When you linking your X Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your X account.

Be alerted of any news about your stocks and see what other stocks are trending.



Connect with Us

Join our Telegram Alerts Channel

Telegram

Join our Discord

Discord

Get GLYC Alerts

Get GLYC Alerts

News, Short Squeeze, Breakout and More Instantly...

Sign up or login to continue

Sign up or login to continue.


Forgot password?




Mobile Number Subscribers

Market Wire News provides notifications to customers about updates, service, reminders, or products. Current and new customers of Market Wire News will enter their mobile numbers on a web opt-in form https://marketwirenews.com. Supported Carriers are as follows Alltel, AT&T, Cincinnati Bell, Dobson Cellular Systems, Inter Op, MetroPCS®, Nextel Communications, Sprint PCS, T-Mobile®, U.S. Cellular®, Verizon Wireless, and Virgin Mobile U.S. T-Mobile® is not liable for delayed or undelivered messages. There are no premium charges for joining Market Wire News service. Message and data rates may apply. Subscribers to Market Wire News service may receive up to 500 per month.

How to Opt Out

To opt-out of the Market Wire News program, send or text STOP, END, QUIT, CANCEL or UNSUBSCRIBE to (844) 931-3999. An unsubscribe message will be sent to your number confirming the cancellation, but no more messages will be sent after that one.

Mobile Support

For support or information about a Market Wire News, send or text HELP to (844) 931-3999. Optionally, you may email support@marketwirenews.com.


Disclaimer

This electronic content is for the purposes of solicitation subscriptions for Market Wire News. Market Wire News expects to generate new advertisement revenue resulting from the distribution of this electronic content. The amount of which is unknown at this time. Market Wire News is not a registered investment adviser or broker-dealer. This electronic content does not provide a professional analysis of a any stock financial position. any stock's financial position and all other information regarding the featured Company should be verified directly with any stock. This electronic content is provided as an information service only, and any statements and opinions in this electronic content should not be construed as an offer or solicitation to buy or sell any security. Market Wire News accepts no liability for any loss arising from an investor's reliance on or use of this electronic content. An investment in any company is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Market Wire News does not own, buy, sell or plans to own, buy, sell, and of any stock's shares. This electronic content contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Please read our full disclaimer for compensation and more detailed information.

Advertise

Brand your company, advertise your products or services with our ad programs.

Advertise

Research

Stock Search

News Releases

Articles

Message Boards

Trending Stocks

Short Information

Stock Wall

Members

Log In

Sign Up

Stay Connected

| X

| Facebook

| BlueSky

| LinkedIn

| Telegram

| Discord


Contact

Privacy

Terms of Service

Disclaimer

© 2025 Market Wire News 1